A 127722

Drug Profile

A 127722

Latest Information Update: 23 Jan 2013

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Anti-ischaemics; Antihypertensives
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cerebral ischaemia; Coronary artery restenosis; Heart failure; Hypertension

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie
  • 04 Dec 2003 No development reported - Preclinical for Cerebral ischaemia in Finland (unspecified route)
  • 04 Dec 2003 No development reported - Preclinical for Congestive heart failure in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top